Position in GSK
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$102,211
+$93,188 QoQ
Shares Held
1,852
+906.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GSK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Anfield Capital Management, LLC holds $889,493 across 12 Drug Manufacturers - General names. GSK ranks #3 (11.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
281 | $258,455 | |
| 2 | MRK |
Merck & Co., Inc.
|
1,338 | $160,948 | |
| 3 | GSK |
GSK plc
This page
|
1,852 | $102,211 | |
| 4 | JNJ |
Johnson & Johnson
|
342 | $83,598 | |
| 5 | AZN |
Astrazeneca PLC
|
385 | $75,929 | |
| 6 | PFE |
Pfizer Inc
|
2,543 | $71,407 | |
| 7 | SNY |
Sanofi
|
1,286 | $61,959 | |
| 8 | NVS |
Novartis AG
|
284 | $43,381 |
All Filings in GSK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $102,211 | 1,852 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $9,023 | 184 | Shares | Defined | 2026-02-03 | |
| 2025-09-30 | $733 | 17 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $76 | 2 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $77 | 2 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $67 | 2 | Shares | Defined | 2025-02-05 | |
| 2024-09-30 | $81 | 2 | Shares | Defined | 2024-11-08 | |
| 2024-06-30 | $77 | 2 | Shares | Defined | 2024-07-31 | |
| 2021-06-30 | $53,701 | 1,375 | Shares | Defined | 2021-08-03 | |
| No filing history on record for this holder in this stock. | ||||||